Authors:
L Hughes-Davies, C Caldas, GC Wishart
Journal name: 
Br J Cancer
Citation info: 
101(6):875-878
Abstract: 
Despite the perception of many oncologists that tamoxifen is an inferior drug, and should be substituted by an aromatase inhibitor in post-menopausal women, the current evidence strongly supports the view that AIs should be used 2-3 years after tamoxifen to achieve the maximal overall survival (OS) advantage.
DOI: 
http://doi.org/10.1038/sj.bjc.6605231
Research group: 
Caldas Group
E-pub date: 
15 Sep 2009